Trajectories of Nicotine and Cannabis Vaping and Polyuse. From Adolescence to Young Adulthood H. Isabella Lanza, PhD; Jessica L. Barrington-Trimis, PhD; RobMcConnell, MD; Junhan Cho, PhD; Jessica L. Braymiller, PhD; Evan A. Krueger, PhD, MPH, MSW; Adam M. Leventhal, PhD JAMA Network Open, 2020, 3, (10), :e2019181. doi : 10.1001/jamanetworkopen.2020.19181 Abstract IMPORTANCE : Little is known about cannabis vaping trajectories across adolescence and young adulthood or the co-occurrence with nicotine vaping. OBJECTIVE : To evaluate nicotine vaping and cannabis vaping trajectories from late adolescence to young adulthood (18 years of age) and the extent of polysubstance vaping. DESIGN, SETTING, AND PARTICIPANTS : In this prospective cohort study, 5 surveys [...]
Lire la suiteReport et nouvelle date pour les 25ES Rencontres du RESPADD : Des drogues en santé mentale Affiche – 25es Rencontres RESPADD En raison de la situation sanitaire actuelle et pour préserver la santé de chacun, le RESPADD a décidé de reporter ses 25es Rencontres. NOUVELLE DATE : le 18 novembre 2020 Les 25es Rencontres professionnelles du RESPADD, réalisées en partenariat avec le Groupement addictions Franche-Comté, la Société psychédélique française et le CHS Saint-Ylie Jura, se tiendront le mercredi 18 novembre 2020 à la Commanderie de Dole. Cette nouvelle édition des Rencontres du RESPADD explorera les nouveaux usages des drogues en santé mentale et [...]
Lire la suiteAvec le confinement: beaucoup de syndromes de manque Benjamin ROLLAND https://www.addictolyon.fr/post/avec-le-confinement-beaucoup-de-syndromes-de-manque Addictolyon, 19/03/2020, Mis à jour : il y a 4 jours Avec le #confinement lié au #COVID19, les trafics de substances semblent s'être fortement réduits. Résultat: en ville, à l'hôpital, en prison, de nombreux syndromes de manque apparaissent. Afin de faciliter la reconnaissance et la prise en charge des syndrome de sevrage chez les patients, voici un petit document explicatif du repérage et du traitement des syndrome de sevrage à catégories importantes de substance: #tabac, #cannabis, et #opioïdes
Lire la suitePsilocybin-Assisted Therapy : A Review of a Novel Treatment for Psychiatric Disorders Kelan Thomas, Pharm.D., M.S., Benjamin Malcolm, Pharm.D., M.P.H., and Dan Lastra, B.S. Journal of Psychoactive Drugs, 2017 Doi : 10.1080/02791072.2017.1320734 Abstract Recent research suggests that functional connectivity changes may be involved in the pathophysiology of psychiatric disorders. Hyperconnectivity in the default mode network has been associated with psycho-pathology, but psychedelic serotonin agonists like psilocybin may profoundly disrupt these dysfunctional neural network circuits and provide a novel treatment for psychiatric disorders. We have reviewed the current literature to investigate the efficacy and safety of psilocybin-assisted therapy for the treatment of psychiatric disorders. There were [...]
Lire la suiteThe association between regular cannabis use, with and without tobacco co-use, and adverse cardiovascular outcomes : cannabis may have a greater impact in non-tobacco smokers Theresa Winhusen, Jeff Theobald, David C. Kaelber, and Daniel Lewis The American Journal of Drug and Alcohol Abuse, 2019 https://doi.org/10.1080/00952990.2019.1676433 ABSTRACT Background : Understanding the potential impact of cannabis use on cardiovascular health is increasingly important as cannabis use rises in the U.S. Objectives : This study evaluated the associations between regular cannabis use, with and without tobacco co-use, and cardiovascular outcomes. Methods : Analysis of a limited dataset obtained through IBM Watson Health Explorys, a platform integrating electronic health record data. [...]
Lire la suiteAssociations of Parental Marijuana Use With Offspring Marijuana, Tobacco, and Alcohol Use and Opioid Misuse Bertha K. Madras, Beth Han, Wilson M. Compton, Christopher M. Jones, Elizabeth I. Lopez, Elinore F. McCance-Katz JAMA Network Open, 2019, 2, (11), e1916015. doi : 10.1001/jamanetworkopen.2019.16015 Abstract IMPORTANCE : Marijuana use is increasing among adults and often co-occurs with other substance use; therefore, it is important to examine whether parental marijuana use is associated with elevated risk of substance use among offspring living in the same household. OBJECTIVE : To examine associations of parental marijuana use with offspring marijuana, tobacco, and alcohol use and opioid misuse. DESIGN, SETTING, AND PARTICIPANTS : [...]
Lire la suiteClinical potential of psilocybine as a treatment for mental health conditions Jeremy Daniel & Margaret Haberman Mental Health Clinician, 2017, Vol. 7, No. 1, pp. 24-28 https://doi.org/10.9740/mhc.2017.01.024 Abstract Psilocybin, a classic hallucinogen, is a chemical produced by more than 100 species of mushrooms worldwide. It has high affinity for several serotonin receptors, including 5-HT1A, 5-HT2A, and 5-HT2C, located in numerous areas of the brain, including the cerebral cortex and thalamus. With legislation introduced in 1992, more work is being done to further understand the implications of psilocybin use in a number of disease states. Certain mental health disease states and symptoms have been studied, including [...]
Lire la suitePsychedelic therapy for smoking cessation : Qualitative analysis of participant accounts Tehseen Noorani, Albert Garcia-Romeu, Thomas C. Swift, Roland R. Griffiths and Matthew W. Johnson Journal of Psychopharmacology, 2018, 1 –14 https://doi.org/10.1177/0269881118780 Abstract Background : Recent pilot trials suggest feasibility and potential efficacy of psychedelic-facilitated addiction treatment interventions. Fifteen participants completed a psilocybin-facilitated smoking cessation pilot study between 2009 and 2015. Aims : The aims of this study were as follows: (1) to identify perceived mechanisms of change leading to smoking cessation in the pilot study; (2) to identify key themes in participant experiences and long-term outcomes to better understand the therapeutic process. Methods : Participants were [...]
Lire la suiteLong-term follow-up of psilocybin-facilitated smoking cessation Johnson M.W., Garcia-Romeu A., Griffiths R.R. The American Journal of Drug and Alcohol Abuse, 2017, 43, (1), 55–60 http://dx.doi.org/10.3109/00952990.2016.1170135 Abstract Background : A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone. Objectives : To assess long-term effects of a psilocybin-facilitated smoking cessation program at ≥12 months after psilocybin administration. Methods : The present [...]
Lire la suiteUsages d’alcool, de tabac et de cannabis chez les adolescents du secondaire en 2018 Stanislas Spilka, Emmanuelle Godeau (EHESP), Olivier Le Nézet, Virginie Ehlinger (Inserm UMR 1027), Eric Janssen, Alex Brissot, Antoine Philippon, Sandra Chyderiotis Tendances, juin 2018 Observatoire français des drogues et des toxicomanies Observer les premiers usages de substances psychoactives chez les adolescents selon le niveau scolaire [1, 2] permet d’analyser le calendrier de diffusion des consommations pour la mise en oeuvre d’actions de prévention et de politiques de santé publique : quand et où intervenir auprès des élèves, quelles sont les classes « pivots » au cours desquelles les expérimentations s’amorcent ou [...]
Lire la suite